STAT+: Pharmalittle: Merck says early data shows pill is effective against Covid-19; WHO’s COVAX program ships first doses
Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, because that oh-so-predictable routine of Zoom meetings, Skype calls and deadlines has returned. After all, the world keeps spinning. With that in mind, why not brew a cup of stimulation and give it a push? Our choice today is the ever-delicious maple bourbon. A fine way to start the day. Meanwhile, here are some tidbits to help you along. Hope your day is productive and do stay safe — wear a mask …
Merck (MRK) reported that an experimental Covid-19 drug, which promises to be a kind of Tamiflu for the pandemic, had positive results in a preliminary study, The Wall Street Journal says. The pill, which is being developed by Ridgeback Therapeutics, significantly reduced infectious virus in subjects in a mid-stage study after five days of treatment. If further study proves it capable of treating people with Covid-19 who show symptoms, the drug would bolster a limited arsenal of treatments and be the first oral antiviral against the disease.
Continue to STAT+ to read the full story…
